All news

No to abiraterone in England & Wales

Added: Friday 9 March 2012

The National Institute for Clinical Excellence (NICE) has said that it will not recommend abiraterone, a drug for men with castration-resistant metastatic prostate cancer. NICE is responsibly for analysing the cost-effectiveness of different drugs for use in the the National Health Service in England and Wales. NICE acknowledged that there is evidence to suggest that abiraterone extends overall survival, but said that cost was the main factor in its negative decision.


+  http://www.oncologystat.com/news/NICE_Issues_Early__No__on_Abiraterone_US.html;jsessionid=81D1F30AE4D5DD3C1F0B62F46B729DEF


//